Human genetic variability and HIV treatment response

Area of Science:

• Pharmacogenomics
• HIV/AIDS Research
• Translational Medicine

Background:

• Antiretroviral medications significantly reduce HIV/AIDS morbidity and mortality.
• Drug toxicity remains a major challenge limiting treatment success in individuals with HIV.
• Pharmacogenomics investigates how human genetic variations influence drug response and toxicity.

Purpose of the Study:

• To explore the role of pharmacogenomics in understanding HIV drug toxicities and virologic responses.
• To highlight the potential of pharmacogenomics in identifying novel therapeutic targets for HIV treatment.
• To emphasize the future benefits of individualized drug prescribing informed by genetic testing for people living with HIV.

Main Methods:

• Identifying associations between human genetic variants and predisposition to HIV drug toxicities.
• Examining genetic variations linked to specific drug responses, such as abacavir hypersensitivity and efavirenz pharmacokinetics.
• Investigating genetic factors influencing HIV receptor (CCR5) function and protection against infection.

Main Results:

• Established links between genetic variants (e.g., HLA type, CYP2B6 polymorphisms) and specific HIV drug toxicities (e.g., abacavir hypersensitivity, CNS symptoms).
• Demonstrated the impact of genetic variations on drug pharmacokinetics and treatment outcomes.
• Showcased how understanding genetic resistance (e.g., CCR5 variants) can drive drug development (e.g., CCR5 antagonists).

Conclusions:

• Pharmacogenomics is crucial for predicting and mitigating HIV drug toxicities.
• Genetic insights are paving the way for developing more effective and targeted HIV therapies.
• Personalized medicine through genetic testing holds significant promise for improving HIV/AIDS treatment outcomes globally.